Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
-
ACADEMIA Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
-
BUSINESS Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
-
BUSINESS Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
-
BUSINESS Top 4 Wholesalers See Over 1% Operating Margins in FY2018, Thanks Partly to Distribution Improvement Guidelines
May 20, 2019
-
REGULATORY Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
-
BUSINESS 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
-
REGULATORY 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
-
REGULATORY Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
-
BUSINESS 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
-
BUSINESS Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
-
BUSINESS Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
-
INTERVIEW As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
-
BUSINESS Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
-
BUSINESS Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
-
TRENDS Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
April 25, 2019
-
BUSINESS Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
-
BUSINESS In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
-
REGULATORY MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
-
INTERVIEW Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
ページ
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…